Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chloroquine with booster vaccination using Engerix-B or F4co/AS01B in healthy adults
2009-012223-29Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2009
- Modality
- Small Molecules, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of chloroquine, Hepatitis B vaccine and F4co/AS01B in hepatitis B (HBV) and human immunodeficiency virus infection (HIV) (2 arms), sponsored by GSK. Primary endpoints: Specific CD8+ T-cell response to F4co/AS01B at Day 14, Specific CD8+ T-cell response to Engerix-B at Day 14 and 2 more. Started Aug 2009; status: completed.
02
Drugs
chloroquineHepatitis B vaccineF4co/AS01B
03
Conditions
hepatitis B (HBV)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2009-012223-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012223-29.